STAT+: Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815M in 2023, report finds
STAT
DECEMBER 12, 2024
During 2023, drugmakers substantially raised prices on five widely used medicines without any new clinical evidence to justify the increases, leading patients and health insurers in the U.S. to spend an additional $815 million last year, according to a new report. The drug for which spending increased the most due to a price increase was Biktarvy, which is prescribed to treat HIV and is a franchise product for Gilead Sciences.
Let's personalize your content